EULAR 2025 highlights… EULAR 2025 Highlights- Rheumatoid Arthritis: Clinical (therapeutic) 18 Jul 2025 Cancer Risk in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Data from a Multicenter National Real-World Registry Abstract format and assignment number: Oral presentation…
ACR Highlights… ACR Convergence 2024 Highlights- Rheumatoid Arthritis: Clinical (therapeutic) 19 Dec 202419 Dec 2024 Efficacy, Safety, Pharmacokinetics of Anti-CD40 Antibody Abiprubart in Patients with Rheumatoid Arthritis: A Phase 2, Randomized, Placebo-Controlled 12-week-treatment Proof-of-Concept Study Abstract format and assignment number: Oral presentation 1678 Presenting author:…
EULAR 2024 Highlights… EULAR 2024 Highlights – RA II – Clinical (therapeutic) 21 Jul 202421 Jul 2024 Author: Daliya Pencheva Aymon et al. (OP0092) assessed the incidence of infections in rheumatoid arthritis (RA) patients from 14 RA registries in the JAK-POT study. Data from 54,905 treatment initiations,…
ACR Highlights… ACR Convergence Highlights 2023 – Rheumatoid Arthritis: Clinical (therapeutic) 9 Dec 20239 Dec 2023 Author: Victoria Konzett Cope et al. (0835) investigated the efficacy of T-cell co-stimulation with Abatacept on prevention of disease onset in an autoantibody-positive population with arthralgia at risk of developing RA,…
Rheumatoid arthritis II - therapeutic… [EULAR HL 2023] Rheumatoid Arthritis II- Clinical- Therapeutic 20 Jun 2023 Author: Lise Verhoef Cope et al. (OP0130) evaluated the feasibility, efficacy and acceptability of 52 weeks of abatacept compared to placebo in 213 individuals at risk of developing rheumatoid arthritis…
Rheumatoid arthritis II - therapeutic… Rheumatoid Arthritis II – Clinical (therapeutic) 29 May 202330 May 2023 Alessandro Giollo Alessandro Giollo currently serves as the lead of refractory arthritis, synovial biopsy and osteoporosis clinics at the Rheumatology Unit, University of Padova (Italy). His clinical work and research…